A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer

Diabetes Research and Clinical Practice

Volumn 98, Issue 2, 2012, Pages 271-284

  Alves, Carlos ^a,b,c   Batel Marques, Francisco ^a,b   Macedo, Ana F ^c  

^a ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Cancer; GLP 1 agonists; Meta analysis; Pancreatitis

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THYROID CANCER; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; NEOPLASMS; PANCREATITIS; PEPTIDES; VENOMS;

EID: 84870508803     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.09.008     Document Type: Article

References (39)

1. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
2. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
3. Madsbad S., Schmitz O., Ranstam J., Jakobsen G., Matthews D.R. NN2211-1310 International Study Group Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN221): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27:1334-1342.
4. Byetta drug approval package. FDA/Centre for Drug Evaluation and Research, available at: ; 2005 [access2nd edn3.05.12]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm.
5. European public assessment report (EPAR) for Byetta. EMA/Committee for Medicinal Products for Human Use, available at: ; 2006 [access2nd edn3.05.12]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/000698/human_med_000682.jsp%26mid=WC0b01ac058001d124.
6. Bydureon label and approval history. FDA/Centre for Drug Evaluation and Research, available at: ; 2012 [access2nd edn3.05.12]. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm%3Ffuseaction=Search.Label_ApprovalHistory%23apphist.
7. European public assessment report (EPAR) for Bydureon. EMA/Committee for Medicinal Products for Human Use, available at: ; 2011 [accessed 23.05.12]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002000/human_med_001457.jsp%26mid=WC0b01ac058001d124.
8. Victoza approval package. FDA/Centre for Drug Evaluation and Research, available at: ; 2010 [accessed 23.05.12]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm.
9. European public assessment report (EPAR) for Victoza. EMA/Committee for Medicinal Products for Human Use, available at: ; 2009 [accessed 23.05.12]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/001026/human_med_001137.jsp%26mid=WC0b01ac058001d124.
10. Drucker D.J., Sherman S.I., Gorelick F.S., Bergenstal R.M., Sherwin R.S., Buse J.B. Increatin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433.
11. FDA alert: information for healthcare professionals: exenatide (marketed as Byetta). FDA/Postmarket Drug Safety Information for Patients and Providers, available at: ; 2007 [accessed 23.05.12]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm.
12. Elashoff M., Matveyenko A.V., Gier B., Elashoff R., Butler P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141:150-156.
13. Raschi E., Piccinni C., Poluzzi E., Marchesini G., De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2011, [published online 19 October; http://dx.doi.org/10.1007/s00592-011-0340-7].
14. Dore D.D., Seeger J.D., Chan K.A. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25:1019-1027.
15. Garg R., Chen W., Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010, 33:2349-2354.
16. Dore D.D., Bloomgren G.L., Wenten M., Hoffman C., Clifford C.R., Quinn S.G., et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011, 13:559-566.
17. Byetta (exenatide) injection-detailed view: safety labelling changes approved by FDA Centre for Drug Evaluation and Research. FDA/MedWatch the FDA Safety Information and Adverse Event Reporting Program, available at: ; 2009 [accessed 23.05.12]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm190571.htm.
18. Parks M., Rosenbraugh C. Weighting risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med 2010, 362:774-777.
19. Bjerre Knudsen L., Madsen L.W., Andersen S., Almholt K., de Boer A.S., Drucker D.J., et al. Glucagon-like peptide-1 receptor agonists active rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151:1473-1486.
20. MSSO medical dictionary for regulatory activities. MedDRA v14.0, available at: [accessed 23.04.12]. http://www.meddramsso.com/index.asp.
21. Downs S.H., Black N. The feasibility of creating a checklist for assessment of the methodological quality of both the randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health 1998, 52:377-384.
22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
23. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analysis. BMJ 2003, 327:557-560.
24. Publication bias., Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. Introduction to meta-analysis 2009, John Wiley & Sons, Chichester, England.
25. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
26. Balani A.R., Grendell J.H. Drug-induced pancreatitis: incidence, management, and prevention. Drug Saf 2008, 31:823-837.
27. Noel R.A., Braun D.K., Patterson R.E., Bloomgren G.L. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes. Diabetes Care 2009, 32:834-838.
28. Anderson S.L., Trujillo M.J. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010, 44(5):904-909.
29. MedWatch. Victoza (liraglutide [rDNA origin]) Injection: REMS - risk of thyroid C-cell tumors, Acute Pancreatitis. FDA/MedWatch the FDA Safety Information and Adverse Event Reporting Program, available at: , 2011 [accessed 23.05.12]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258826.htm.
30. Butler P.C., Dry S., Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010, 33:453-455.
31. Butler A.E., Galasso R., Matveyenko A.V., Rizza R.A., Dry S., Butler P.C. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010, 53:21-26.
32. Koehler J.A., Baggio L.L., Lamont B.J., Ali S., Drucker D.J. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009, 58:2148-2161.
33. Nachnani J.S., Bulchandani D.G., Nookala A., Herndon B., Molteni A., Pandya P., et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010, 53:153-159.
34. Vrang N., Jelsing J., Simonsen L., Jensen A.E., Thorup I., Søeborg H., et al. The effects of 13weeks of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF-rats: no evidence of drug induced pancreatitis. Am J Physiol Endocrinol Metab 2012, [published online 15 May, http://dx.doi.org/10.1152/ajpendo.00182.2012].
35. Jüni P., Witschi A., Bloch R., Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999, 282:1054-1060.
36. Parola T. Victoza® (liraglutide injection): human relevance of rodent thyroid C-cell tumors. FDA/Endocrinologic and Metabolic Drugs Advisory Committee Meeting, available at: ; 2009 [accessed 23.05.12]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151129.pdf.
37. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (Exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
38. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and sulfonylurea. Diabetes Care 2005, 28:1083-1091.
39. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A., et al. Effects of exenatide (Exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.